NCT06720896
A Phase 2, Controlled, Double Blind, Randomized and Multicenter Study to Compare Efficacy and Safety of a Novel Topical Therapy (APT-001, Spinosad 1.8%) in Patients With Blepharitis.
Phase: Phase 2
Role: Lead Sponsor
Start: Sep 30, 2025
Completion: Feb 28, 2026